| Primary information |
|---|
| ID | antitb_1135, |
| Name | 11328767 |
| N-Terminal modification | Protegrin-1 (PG-1) |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Internal disulphide bond (between Cys 6-15 and Cys 8-13) |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Isolated from porcine leukocytes |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis E1380/94 MDR (Isoniazid, rifampicin, streptomycin, ethambutol) strain |
| Cell Line | 50 mg/L causes approx 39 % growth inhibition |
| Inhibition Concentration | In vitro |
| Sequence | 2001 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Disrupt the membrane architecture |
| Other activities | Cell envelope |
| PMID | None |
| Year of Publication | Antibacterial against salmonella, staphylococcus and neisseria |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1563, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | CFU/well 3.20 ± 0.15 at peptide concentration 64μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1564, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | CFU/well 2.70 ± 0.15 at peptide concentration 64μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1565, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | CFU/well 0.88± 0.30 at peptide concentration 4 μg/ml +INH 0.06 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | INH +peptide |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1566, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | CFU/well 3.19 ± 0.15 at peptide concentration 64 μg/ml +INH 0.06 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | INH+Peptide |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1567, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | CFU/well 3.19 ± 0.15 at peptide concentration 4 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1568, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | CFU/well 3.58 ± 0.47 at peptide concentration 8 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1569, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | CFU/well 3.16 ± 0.21 at peptide concentration 16 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1570, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | CFU/well 2.97 ± 0.40 at peptide concentration 32 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1571, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | CFU/well 2.70 ± 0.10 at peptide concentration 64 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1572, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | CFU/well 1.72 ± 0.46 at peptide concentration 128 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1573, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis RM22 |
| Cell Line | CFU/well 3.08 ± 0.09 at peptide concentration 4 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1574, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 19 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis RM23 |
| Cell Line | CFU/well 2.97 ± 0.06 at peptide concentration 4 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1575, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 20 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis RM24 |
| Cell Line | CFU/well 3.11 ± 0.09 at peptide concentration 4 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1576, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 21 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis RM25 |
| Cell Line | CFU/well 3.19 ± 0.05 at peptide concentration 4 μg/ml +INH 4μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1577, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 22 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis RM26 |
| Cell Line | CFU/well 3.08 ± 0.09 at peptide concentration 64 μg/ml +INH 4μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1578, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis RM22 |
| Cell Line | CFU/well 3.10 ± 0.08 at peptide concentration 8 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1579, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis RM22 |
| Cell Line | CFU/well 3.00 ± 0.10 at peptide concentration 16 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1580, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis RM22 |
| Cell Line | CFU/well 3.05 ± 0.11 at peptide concentration 32 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1581, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis RM22 |
| Cell Line | CFU/well 2.88 ± 0.06at peptide concentration 64 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1582, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis RM22 |
| Cell Line | CFU/well 2.71 ± 0.09 at peptide concentration 128 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1603, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | CFU/well 0.68 ± 0.30 at peptide 64ul + 4 ul of INH |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | Peptide(64 ul) + INH(4 ul) |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1604, |
| Name | 15245864 |
| N-Terminal modification | Protegrin -1 |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-14 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from porcine leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis RM22 |
| Cell Line | CFU/well 1.99 ± 0.44 at peptide 64ul + 4 ul of INH |
| Inhibition Concentration | in vitro |
| Sequence | 2004 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bacterial membrane pore formation |
| Other activities | NA |
| PMID | Peptide(64 ul) + INH(4 ul) |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1708, |
| Name | 8641802 |
| N-Terminal modification | Porcine leucocyte peptide (PG-1) |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-13 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | porcine neutrophil leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis Ra 7632G |
| Cell Line | Reduction in CFU at 50 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1996 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1709, |
| Name | 8641802 |
| N-Terminal modification | Porcine leucocyte peptide (PG-1) |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-14 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | porcine neutrophil leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis Ra 9034G |
| Cell Line | Reduction in CFU at 50 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1996 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1710, |
| Name | 8641802 |
| N-Terminal modification | Porcine leucocyte peptide (PG-1) |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-15 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | porcine neutrophil leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis Ra 11170G |
| Cell Line | Reduction in CFU at 50 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1996 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1711, |
| Name | 8641802 |
| N-Terminal modification | Porcine leucocyte peptide (PG-1) |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-16 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | porcine neutrophil leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37 Ra |
| Cell Line | IC50= 5 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1996 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1712, |
| Name | 8641802 |
| N-Terminal modification | Porcine leucocyte peptide (PG-1) |
| C-Terminal Modification | RGGRLCYCRRRFCVCVGR |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | Disulphide linkage 6-15 and 8-17 |
| Chirality | Cyclic |
| Nature | 18 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | porcine neutrophil leucocyte |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37 Ra |
| Cell Line | MIC = 50 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1996 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |